Seelos Therapeutics Inc (SEEL)
0.92
-0.11
(-10.68%)
USD |
OTCM |
Nov 04, 15:59
Seelos Therapeutics Net Income (Quarterly): 1.71M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.71M |
| March 31, 2024 | -2.664M |
| December 31, 2023 | -5.453M |
| September 30, 2023 | 10.50M |
| June 30, 2023 | -29.50M |
| March 31, 2023 | -13.43M |
| December 31, 2022 | -18.66M |
| September 30, 2022 | -19.60M |
| June 30, 2022 | -21.27M |
| March 31, 2022 | -14.00M |
| December 31, 2021 | -27.26M |
| September 30, 2021 | -10.82M |
| June 30, 2021 | -8.858M |
| March 31, 2021 | -19.12M |
| December 31, 2020 | -6.45M |
| September 30, 2020 | -4.09M |
| June 30, 2020 | -3.729M |
| March 31, 2020 | -4.832M |
| December 31, 2019 | -10.66M |
| September 30, 2019 | -3.221M |
| June 30, 2019 | -1.863M |
| March 31, 2019 | -35.51M |
| December 31, 2018 | -6.987M |
| September 30, 2018 | -1.097M |
| June 30, 2018 | -2.277M |
| Date | Value |
|---|---|
| March 31, 2018 | -2.271M |
| December 31, 2017 | -2.446M |
| September 30, 2017 | -3.832M |
| June 30, 2017 | -1.474M |
| March 31, 2017 | 8.073M |
| December 31, 2016 | -0.299M |
| September 30, 2016 | -1.291M |
| June 30, 2016 | -3.338M |
| March 31, 2016 | -2.505M |
| December 31, 2015 | -2.332M |
| September 30, 2015 | -5.034M |
| June 30, 2015 | -5.245M |
| March 31, 2015 | -6.412M |
| December 31, 2014 | -17.29M |
| September 30, 2014 | -3.113M |
| June 30, 2014 | 1.877M |
| March 31, 2014 | -3.262M |
| December 31, 2013 | -1.345M |
| September 30, 2013 | -2.985M |
| June 30, 2013 | -3.935M |
| March 31, 2013 | -8.673M |
| December 31, 2012 | -19.64M |
| September 30, 2012 | -2.494M |
| June 30, 2012 | -4.926M |
| March 31, 2012 | -4.713M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-29.50M
Minimum
Jun 2023
10.50M
Maximum
Sep 2023
-10.96M
Average
-10.66M
Median
Dec 2019
Net Income (Quarterly) Benchmarks
| 180 Life Sciences Corp | 0.0118M |
| Cassava Sciences Inc | 6.155M |
| Cara Therapeutics Inc | -20.02M |
| Citius Pharmaceuticals Inc | -10.57M |
| Moleculin Biotech Inc | -4.319M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.139M |
| EPS Diluted (Quarterly) | 1.92 |
| Enterprise Value | 10.27M |
| Earnings Yield | -51.69K% |